The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study: Insulin secretion following CFTR correction
Open accessAbstract
OBJECTIVE: To determine whether the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is involved in human insulin secretion by assessing the metabolic impact of the new CFTR corrector-ivacaftor. METHODS: This open-label pilot study was conducted in CF patients with the G551D mutation given new prescriptions for ivacaftor. At baseline and 4 wk after daily ivacaftor therapy, intravenous glucose tolerance tests (IVGTT) and oral glucose tolerance tests (OGTT) were performed. RESULTS: Five patients aged 6-52 were studied. After 1 month on ivacaftor, the insulin response to oral glucose improved by 66-178% in all subjects except one with long-standing diabetes. OGTT glucose levels were not lower in the two individuals with diabetes or the two with normal glucose tolerance (NGT), but the glucose tolerance category in the subject with impaired glucose tolerance (IGT) improved to NGT after treatment. In response to intravenous glucose, the only patient whose acute insulin secretion did not improve had newly diagnosed, untreated CFRD. The others improved by 51-346%. Acute insulin secretion was partially restored in two subjects with no measurable acute insulin response at baseline, including the one with IGT and the one with long-standing diabetes. CONCLUSIONS: This small pilot study suggests there is a direct role of CFTR in human insulin secretion. Larger, long-term longitudinal studies are necessary to determine whether early initiation of CFTR correction, particularly in young children with CF who have not yet lost considerable β-cell mass, will delay or prevent development of diabetes in this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195 · cited 1×
“In clinical Phase 2 and 3 trials, ivacaftor produced dramatic improvements in skin sweat chloride levels and in lung function within just 3 wk (9, 10), and the drug has recently been approved by the FDA in children down to age 6.”
Background
Cited by
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Progress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
Volkova, N., Moy, K., Evans, J., Campbell, D., Tian, S., Simard, C., Higgins, M., Konstan, M. W., Sawicki, G. S., Elbert, A., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.015 · Cited by 258
Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210394 · Cited by 214
“22 In a number of earlier small studies, ivacaftor appeared to improve insulin response to oral glucose, 23 reduce levels of haemoglobin A1c (suggesting improved glycaemic control) 24 and reduce insulin requirement in a patient with existing CF-related diabetes.”
ResultMoran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12732 · Cited by 171
Self-citationGuo, J. H., Chen, H., Ruan, Y. C., Zhang, X. L., Zhang, X. H., Fok, K. L., Tsang, L. L., Yu, M. K., Huang, W. Q., Sun, X., et al. (2014) · Nature Communications · doi:10.1038/ncomms5420 · Cited by 157
CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis
Balfour-Lynn, I. M., & King, J. A. (2022) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.05.002 · Cited by 85
New insights into cystic fibrosis-related diabetes in children
Ode, K. L., & Moran, A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70015-9 · Cited by 76
Self-citationCFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells
Edlund, A., Pedersen, M. G., Lindqvist, A., Wierup, N., Flodström-Tullberg, M., & Eliasson, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-00098-8 · Cited by 63
Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis
Prentice, B. J., Chelliah, A., Ooi, C. Y., Hameed, S., Verge, C. F., Plush, L., & Widger, J. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.005 · Cited by 39
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
Self-citationNew Therapies to Correct the Cystic Fibrosis Basic Defect
Bergeron, C., & Cantin, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126193 · Cited by 22
Metadata
- Authors
- Bellin, M. D., Laguna, T., Leschyshyn, J., Regelmann, W., Dunitz, J., Billings, J., & Moran, A.
- Venue
- Pediatric Diabetes
- Publisher
- Hindawi Limited
- Published
- 2013-03-13
- Volume
- 14
- Issue
- 6
- Pages
- 417-421
- ISSN
- 1399-543X (ISSN-L)
- OpenAlex
- W1559981541
- Cited by
- 193
- References
- 1
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.